Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma - PubMed (original) (raw)
. 2001 Jan 15;61(2):509-12.
Affiliations
- PMID: 11212242
Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma
D Valmori et al. Cancer Res. 2001.
Abstract
MAGE genes encode tumor-specific shared antigens that are among the most interesting candidates for cancer vaccines. Despite extensive studies, however, CD8+ T-cell responses to MAGE-derived epitopes have been detected only occasionally in cancer patients, even after vaccination. In contrast with these findings, we report here that HLA-A2 melanoma patients respond frequently to the recently identified peptide MAGE-A10(254-262). Indeed, as assessed by staining with fluorescent HLA-A2/peptide MAGE-A10(254-262) tetramers, CD8+ T cells directed against this peptide were readily detectable in a large proportion of HLA-A2+ melanoma patients. These results provide new insight into the immunogenicity of MAGE antigens and underline the potential usefulness of MAGE-A10 peptide-based cancer vaccines.
Similar articles
- Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.
Dutoit V, Rubio-Godoy V, Dietrich PY, Quiqueres AL, Schnuriger V, Rimoldi D, Liénard D, Speiser D, Guillaume P, Batard P, Cerottini JC, Romero P, Valmori D. Dutoit V, et al. Cancer Res. 2001 Aug 1;61(15):5850-6. Cancer Res. 2001. PMID: 11479225 - Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
Valmori D, Liénard D, Waanders G, Rimoldi D, Cerottini JC, Romero P. Valmori D, et al. Cancer Res. 1997 Feb 15;57(4):735-41. Cancer Res. 1997. PMID: 9044853 - Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.
Huang LQ, Brasseur F, Serrano A, De Plaen E, van der Bruggen P, Boon T, Van Pel A. Huang LQ, et al. J Immunol. 1999 Jun 1;162(11):6849-54. J Immunol. 1999. PMID: 10352307 - Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
Fujie T, Tanaka F, Mori M, Takesako K, Sugimachi K, Akiyoshi T. Fujie T, et al. Clin Cancer Res. 1997 Dec;3(12 Pt 1):2425-30. Clin Cancer Res. 1997. PMID: 9815643 - Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.
Coulie PG, Karanikas V, Lurquin C, Colau D, Connerotte T, Hanagiri T, Van Pel A, Lucas S, Godelaine D, Lonchay C, Marchand M, Van Baren N, Boon T. Coulie PG, et al. Immunol Rev. 2002 Oct;188:33-42. doi: 10.1034/j.1600-065x.2002.18804.x. Immunol Rev. 2002. PMID: 12445279 Review.
Cited by
- Methionine oxidation selectively enhances T cell reactivity against a melanoma antigen.
Chiriţoiu GN, Munteanu CVA, Şulea TA, Spiridon L, Petrescu AJ, Jandus C, Romero P, Petrescu ŞM. Chiriţoiu GN, et al. iScience. 2023 Jun 25;26(7):107205. doi: 10.1016/j.isci.2023.107205. eCollection 2023 Jul 21. iScience. 2023. PMID: 37485346 Free PMC article. - Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention.
Jacqueline C, Finn OJ. Jacqueline C, et al. Semin Immunol. 2020 Feb;47:101394. doi: 10.1016/j.smim.2020.101394. Epub 2020 Apr 6. Semin Immunol. 2020. PMID: 32273212 Free PMC article. Review. - Antibody response against cancer-testis antigens MAGEA4 and MAGEA10 in patients with melanoma.
Õunap K, Kurg K, Võsa L, Maiväli Ü, Teras M, Planken A, Ustav M, Kurg R. Õunap K, et al. Oncol Lett. 2018 Jul;16(1):211-218. doi: 10.3892/ol.2018.8684. Epub 2018 May 10. Oncol Lett. 2018. PMID: 29928403 Free PMC article. - Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells.
Kirkin AF, Dzhandzhugazyan KN, Guldberg P, Fang JJ, Andersen RS, Dahl C, Mortensen J, Lundby T, Wagner A, Law I, Broholm H, Madsen L, Lundell-Ek C, Gjerstorff MF, Ditzel HJ, Jensen MR, Fischer W. Kirkin AF, et al. Nat Commun. 2018 Mar 6;9(1):785. doi: 10.1038/s41467-018-03217-9. Nat Commun. 2018. PMID: 29511178 Free PMC article. Clinical Trial. - MAGE-A Antigens and Cancer Immunotherapy.
Zajac P, Schultz-Thater E, Tornillo L, Sadowski C, Trella E, Mengus C, Iezzi G, Spagnoli GC. Zajac P, et al. Front Med (Lausanne). 2017 Mar 8;4:18. doi: 10.3389/fmed.2017.00018. eCollection 2017. Front Med (Lausanne). 2017. PMID: 28337438 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials